Role of the PPAR-α agonist fenofibrate in severe pediatric burn

Itoro E. Elijah, Elisabet Børsheim, Dirk M. Maybauer, Celeste C. Finnerty, David N. Herndon, Marc O. Maybauer

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades. Its receptors are expressed in the liver, skeletal muscle, cardiac, enteric, and renal cells, which allow it to provide systemic regulation of lipoprotein metabolism, fatty acid oxidation, and fatty acid transport. Hyperglycemia is a common complication found in the burn population because hepatic glucose production and catecholamine-mediated hepatic glycogenolysis are augmented. Insulin resistance occurs often in these patients and is associated with poor outcomes. In the pediatric burn population, fenofibrate has been found to ameliorate or decrease the number of hypoglycemic episodes when compared to management with insulin alone. Its mechanism of action is thought to involve an improvement in insulin signaling in skeletal muscle, as well as improvements in mitochondrial function, glucose oxidation, and insulin sensitivity. The long term use of fenofibrate in severely burned patients may improve hyperglycemia and insulin resistance, as well as improve wound healing, and reduce apoptosis, and oxidative stress.

Original languageEnglish (US)
Pages (from-to)481-486
Number of pages6
Issue number4
StatePublished - Jun 2012


  • Burns
  • Fenofibrate
  • Hypermetabolism
  • Insulin
  • Lipolysis
  • PPAR

ASJC Scopus subject areas

  • Surgery
  • Emergency Medicine
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Role of the PPAR-α agonist fenofibrate in severe pediatric burn'. Together they form a unique fingerprint.

Cite this